Fragility of Evidence for the Efficacy of Anti-Fracture Medications - Takeaways - MDSpire

Fragility of Evidence for the Efficacy of Anti-Fracture Medications

  • By

  • Nick Tran

  • Thach S Tran

  • Tuan V Nguyen

  • June 9, 2025

  • 0 min

Share

  • 1

    The study analyzed 27 phase 3/4 RCTs to assess the fragility of evidence supporting anti-fracture treatment efficacy.

  • 2

    The median Fragility Index (FI) was 9, indicating that adding 9 patients could negate the evidence of anti-fracture efficacy.

  • 3

    In 60% of analyses, the number of participants lost to follow-up exceeded the corresponding FI, highlighting evidence fragility.

  • 4

    Romosozumab showed the most robust evidence for anti-fracture efficacy, while denosumab and calcium/vitamin D had the least.

  • 5

    The findings suggest incorporating FI and Fragility Quotient into clinical guidelines and risk communication for osteoporosis management.

Original Source(s)

Fragility of Evidence for the Efficacy of Anti-Fracture Medications

  • by Nick Tran, Thach S Tran, Tuan V Nguyen

  • June 9, 2025

Related Content

The role of gut microbiota in osteoporosis: underlying mechanisms, clinical associations, and emerging biomaterials

Cardiovascular Implications of Osteoporosis Treatments: Understanding the Role of Vascular Calcification and Sclerostin Pathways

MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss